|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang SJ, Emery R, Fuller CD, Kim JS,
Sittig DF and Thomas CR: Conditional survival in gastric cancer: a
SEER database analysis. Gastric Cancer. 10:153–158. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verdecchia A, Santaquilani M and Sant M:
Survival for cancer patients in Europe. Ann Ist Super Sanita.
45:315–324. 2009.PubMed/NCBI
|
|
4
|
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK
and Kim WH: EGFR in gastric carcinomas: prognostic significance of
protein overexpression and high gene copy number. Histopathology.
52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liang Z, Zeng X, Gao J, et al: Analysis of
EGFR, HER2, and TOP2A gene status and chromosomal polysomy in
gastric adenocarcinoma from Chinese patients. BMC Cancer.
8:3632008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pinto C, Di Fabio F, Barone C, et al:
Phase II study of cetuximab in combination with cisplatin and
docetaxel in patients with untreated advanced gastric or
gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J
Cancer. 101:1261–1268. 2009. View Article : Google Scholar
|
|
7
|
Lordick F, Luber B, Lorenzen S, et al:
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line
metastatic gastric cancer: a phase II study of the
Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer.
102:500–505. 2010. View Article : Google Scholar
|
|
8
|
Kim C, Lee JL, Ryu MH, et al: A
prospective phase II study of cetuximab in combination with XELOX
(capecitabine and oxaliplatin) in patients with metastatic and/or
recurrent advanced gastric cancer. Invest New Drugs. 29:366–373.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luber B, Deplazes J, Keller G, et al:
Biomarker analysis of cetuximab plus
oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic
gastric and oesophago-gastric junction cancer: results from a phase
II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
BMC Cancer. 11:5092011. View Article : Google Scholar
|
|
10
|
Lievre A, Bachet JB, Le Corre D, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goldstein NI, Prewett M, Zuklys K,
Rockwell P and Mendelsohn J: Biological efficacy of a chimeric
antibody to the epidermal growth factor receptor in a human tumor
xenograft model. Clin Cancer Res. 1:1311–1318. 1995.PubMed/NCBI
|
|
12
|
Harris RC, Chung E and Coffey RJ: EGF
receptor ligands. Exp Cell Res. 284:2–13. 2003. View Article : Google Scholar
|
|
13
|
Higashiyama S, Abraham JA, Miller J,
Fiddes JC and Klagsbrun M: A heparin-binding growth factor secreted
by macrophage-like cells that is related to EGF. Science.
251:936–939. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Komurasaki T, Toyoda H, Uchida D and
Morimoto S: Epiregulin binds to epidermal growth factor receptor
and ErbB-4 and induces tyrosine phosphorylation of epidermal growth
factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene. 15:2841–2848.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shoyab M, Plowman GD, McDonald VL, Bradley
JG and Todaro GJ: Structure and function of human amphiregulin: a
member of the epidermal growth factor family. Science.
243:1074–1076. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Strachan L, Murison JG, Prestidge RL,
Sleeman MA, Watson JD and Kumble KD: Cloning and biological
activity of epigen, a novel member of the epidermal growth factor
superfamily. J Biol Chem. 276:18265–18271. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Watanabe T, Shintani A, Nakata M, et al:
Recombinant human betacellulin. Molecular structure, biological
activities, and receptor interaction. J Biol Chem. 269:9966–9973.
1994.PubMed/NCBI
|
|
18
|
Prewett M, Rockwell P, Rockwell RF, et al:
The biologic effects of C225, a chimeric monoclonal antibody to the
EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor
Immunol. 19:419–427. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Khambata-Ford S, Garrett CR, Meropol NJ,
et al: Expression of epiregulin and amphiregulin and K-ras mutation
status predict disease control in metastatic colorectal cancer
patients treated with cetuximab. J Clin Oncol. 25:3230–3237. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jacobs B, De Roock W, Piessevaux H, et al:
Amphiregulin and epiregulin mRNA expression in primary tumors
predicts outcome in metastatic colorectal cancer treated with
cetuximab. J Clin Oncol. 27:5068–5074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bardelli A and Siena S: Molecular
mechanisms of resistance to cetuximab and panitumumab in colorectal
cancer. J Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Krumbach R, Schuler J, Hofmann M,
Giesemann T, Fiebig HH and Beckers T: Primary resistance to
cetuximab in a panel of patient-derived tumour xenograft models:
activation of MET as one mechanism for drug resistance. Eur J
Cancer. 47:1231–1243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liska D, Chen CT, Bachleitner-Hofmann T,
Christensen JG and Weiser MR: HGF rescues colorectal cancer cells
from EGFR inhibition via MET activation. Clin Cancer Res.
17:472–482. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Heindl S, Eggenstein E, Keller S, et al:
Relevance of MET activation and genetic alterations of KRAS and
E-cadherin for cetuximab sensitivity of gastric cancer cell lines.
J Cancer Res Clin Oncol. Jan 31–2012.(Epub ahead of print).
|
|
25
|
Kim IJ, Park JH, Kang HC, et al:
Mutational analysis of BRAF and K-ras in gastric cancers: absence
of BRAF mutations in gastric cancers. Hum Genet. 114:118–120. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han SW, Oh DY, Im SA, et al: Phase II
study and biomarker analysis of cetuximab combined with modified
FOLFOX6 in advanced gastric cancer. Br J Cancer. 100:298–304. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Paull KD, Shoemaker RH, Hodes L, et al:
Display and analysis of patterns of differential activity of drugs
against human tumor cell lines: development of mean graph and
COMPARE algorithm. J Natl Cancer Inst. 81:1088–1092. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boyd MR and Paull KD: Some practical
considerations and applications of the National Cancer Institute in
vitro anticancer drug discovery screen. Drug Dev Res. 34:91–109.
1995. View Article : Google Scholar
|
|
29
|
Luo FR, Yang Z, Dong H, et al: Correlation
of pharmacokinetics with the antitumor activity of Cetuximab in
nude mice bearing the GEO human colon carcinoma xenograft. Cancer
Chemother Pharmacol. 56:455–464. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Robert F, Ezekiel MP, Spencer SA, et al:
Phase I study of anti-epidermal growth factor receptor antibody
cetuximab in combination with radiation therapy in patients with
advanced head and neck cancer. J Clin Oncol. 19:3234–3243.
2001.PubMed/NCBI
|
|
31
|
Baselga J, Pfister D, Cooper MR, et al:
Phase I studies of anti-epidermal growth factor receptor chimeric
antibody C225 alone and in combination with cisplatin. J Clin
Oncol. 18:904–914. 2000.PubMed/NCBI
|
|
32
|
Loughrey MB, Waring PM, Tan A, et al:
Incorporation of somatic BRAF mutation testing into an algorithm
for the investigation of hereditary non-polyposis colorectal
cancer. Fam Cancer. 6:301–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pan Q, Pao W and Ladanyi M: Rapid
polymerase chain reaction-based detection of epidermal growth
factor receptor gene mutations in lung adenocarcinomas. J Mol
Diagn. 7:396–403. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Marchetti A, Martella C, Felicioni L, et
al: EGFR mutations in non-small-cell lung cancer: analysis of a
large series of cases and development of a rapid and sensitive
method for diagnostic screening with potential implications on
pharmacologic treatment. J Clin Oncol. 23:857–865. 2005. View Article : Google Scholar
|
|
35
|
Bremm A, Walch A, Fuchs M, et al: Enhanced
activation of epidermal growth factor receptor caused by
tumor-derived E-cadherin mutations. Cancer Res. 68:707–714. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Agarwal S, Zerillo C, Kolmakova J, et al:
Association of constitutively activated hepatocyte growth factor
receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in
non-small-cell lung cancer cells. Br J Cancer. 100:941–949. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo A, Villen J, Kornhauser J, et al:
Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl
Acad Sci USA. 105:692–697. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Asaoka Y, Tada M, Ikenoue T, et al:
Gastric cancer cell line Hs746T harbors a splice site mutation of
c-Met causing juxta-membrane domain deletion. Biochem Biophys Res
Commun. 394:1042–1046. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tinhofer I, Klinghammer K, Weichert W, et
al: Expression of amphiregulin and EGFRvIII affect outcome of
patients with squamous cell carcinoma of the head and neck
receiving cetuximab-docetaxel treatment. Clin Cancer Res.
17:5197–5204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yonesaka K, Zejnullahu K, Lindeman N, et
al: Autocrine production of amphiregulin predicts sensitivity to
both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer
Res. 14:6963–6973. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yasumoto K, Yamada T, Kawashima A, et al:
The EGFR ligands amphiregulin and heparin-binding egf-like growth
factor promote peritoneal carcinomatosis in CXCR4-expressing
gastric cancer. Clin Cancer Res. 17:3619–3630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kitadai Y, Yasui W, Yokozaki H, et al:
Expression of amphiregulin, a novel gene of the epidermal growth
factor family, in human gastric carcinomas. Jpn J Cancer Res.
84:879–884. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dong J, Opresko LK, Chrisler W, et al: The
membrane-anchoring domain of epidermal growth factor receptor
ligands dictates their ability to operate in juxtacrine mode. Mol
Biol Cell. 16:2984–2998. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Inno A, Salvatore MD, Cenci T, et al: Is
there a role for IGF1R and c-MET pathways in resistance to
cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer.
10:325–332. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Stommel JM, Kimmelman AC, Ying H, et al:
Coactivation of receptor tyrosine kinases affects the response of
tumor cells to targeted therapies. Science. 318:287–290. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim IJ, Park JH, Kang HC, et al:
Mutational analysis of BRAF and K-ras in gastric cancers: absence
of BRAF mutations in gastric cancers. Hum Genet. 114:118–120. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mita H, Toyota M, Aoki F, et al: A novel
method, digital genome scanning detects KRAS gene amplification in
gastric cancers: involvement of overexpressed wild-type KRAS in
downstream signaling and cancer cell growth. BMC Cancer. 9:1982009.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki
H, Ito H and Tahara E: Frequent amplification of the c-met gene in
scirrhous type stomach cancer. Biochem Biophys Res Commun.
189:227–232. 1992. View Article : Google Scholar : PubMed/NCBI
|
